Trials / Completed
CompletedNCT00600964
A Phase I/II Study of GX15-070MS in Untreated CLL
A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Gemin X · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.
Detailed description
Both 1 hour and 3 hour infusions of obatoclax every 3 weeks will be evaluated in ascending doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GX15-070MS | A 60-minute or 3-hour IV infusion every 2-3 weeks. |
| DRUG | GX15-070MS | GX15-070MS at various doses and schedules |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2008-01-25
- Last updated
- 2014-05-12
Locations
5 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00600964. Inclusion in this directory is not an endorsement.